The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus

References

• Sittl R. Transdermal buprenorphine in clinical practice. In: Budd Kand Raffa R, eds. Buprenorphine – the Unique Opioid Analgesic. Stuttgart: Thieme, 2005
   Google Scholar
• Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982;50:1913-18
   PubMed Web of Science ®Google Scholar
• Bonica JJ. Evolution and current status of pain programs. J Pain Symptom Manage 1990;5:368-74
   PubMedGoogle Scholar
• Cleeland CS, Hatfield AK, Edmonson JH, et al. Pain and its treatment in patients with metastatic cancer. N Engl J Med 1994;330:592-6
   PubMed Web of Science ®Google Scholar
• WHO's Pain Ladder. Geneva: World Health Organization. Available from: www.who.int/cancer/palliative/painladder/en [Last accessed February 2009]
   Google Scholar
• Boas RA, Villiger RW. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth 1985;57:192-6
   PubMed Web of Science ®Google Scholar
• Tzschentke T. Behavioural pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology 2002;161:1-16
   PubMed Web of Science ®Google Scholar
• Cowan A. Update on the general pharmacology of buprenorphine. In: Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York: Wiley-Liss, 1995:31-47
   Google Scholar
• Christoph T, Kögel B, Schiene K, et al. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005;507:87-98
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Bigelow GE, et al. Acute administration of buprenorphine in humans: portial agonist and blockade effects. J Pharmacol Exp Ther 1995;274:361-72
   PubMed Web of Science ®Google Scholar
• Raffa B, Ding Z. Examination of the preclinical and antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. Acute Pain 2007;9:145-52
   Google Scholar
• Greenwald MK, Johanson C-E, Moody De, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin dependent volunteers. Neuropsychopharmacotherapy 2003;28:900-3
   Web of Science ®Google Scholar
• Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomized, double-blind placebo-controlled study. Pain Clinic 2003;15:193-220
   Web of Science ®Google Scholar
• Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders. A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003;25:150-68
   PubMed Web of Science ®Google Scholar
• Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, placebo-controlled study. Clin Ther 2004;26:1808-20
   PubMed Web of Science ®Google Scholar
• Likar R, Kayser H, Sittl R. Long-term treatment of chronic pain with transdermal buprenorphine. Results of an open-label, multicentre follow-up study. Clin Ther 2006;28:943-52
   PubMed Web of Science ®Google Scholar
• Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005;21:1147-56
   PubMed Web of Science ®Google Scholar
• Muriel C, Failde I, Mico JA, et al. Effectiveness and safety of transdermal buprenorphine in patients with moderate to severe pain: results of a non-interventional multicenter study. Clin Ther 2005;27:451-62
   PubMed Web of Science ®Google Scholar
• Camba M, Rodriguez-Lopez M, Muriel C, and the Opioid Study Group of the Spanish Pain Society. Buprenorphine TDS in the treatment of chronic, nociceptive, neuropathic and cancer-related pain. J Appl Ther Res 2007;6:3-13
   Google Scholar
• Barutell C de, Gonzalez-Escalada J, and the Opioid Study Group of the Spanish Pain Society. Efficacy and safety of buprenorphine TDS in conjunction with oral tramadol or morphine as rescue medication in the treatment of 390 patients with chronic pain: a summary or two retrospective Spanish multicentre studies. J Appl Ther Res 2007;6:14-24
   Google Scholar
• Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005;94:825-34
   PubMed Web of Science ®Google Scholar
• Sacerdote P. Opioids and the immune system. Palliat Med 2006;20:9-15
   PubMed Web of Science ®Google Scholar
• Mercadante S, Arcuri I. Opioids and renal function. J Pain 2004;5:2-19
   PubMed Web of Science ®Google Scholar
• Filitz J, Griessinger N, Sittl R. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 2006;10:743-8
   PubMed Web of Science ®Google Scholar
• Merskey H, Bogduk N, eds. Classification of Chronic Pain, 2nd edn. IASP Task Force on Taxonomy. Seattle: IASP Press, 1994
   Google Scholar
• Datamonitor, Treatment Algorithms: Cancer Pain. DMHC1823. London: Datamonitor, 2003
   Google Scholar
• Freyenhagen R, Baron R, Gockel U, et al. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20
   PubMed Web of Science ®Google Scholar
• Dworkin R, O’Connor , Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:225-6
   PubMed Web of Science ®Google Scholar
• Kouya PF. Buprenorphine alleviates neuropathic pain-like behaviour in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol 2002;450:49-53
   PubMed Web of Science ®Google Scholar
• Koppert W, Ihmsen H, Körber N, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005;118:15-22
   PubMed Web of Science ®Google Scholar
• Rodriguez-Lopez M. Transdermal buprenorphine in the management of neuropathic pain. Rev Soc Esp Dolor 2004;11 (Suppl V):11-21
   Google Scholar
• Orts R. Saldaña, Hermira A. Transdermal buprenorphine in the treatment of neuropathic pain. Eur J Pain 2006;10 (Suppl 1):S180 (Abstr. 689)
   Google Scholar
• Duse G. Efficacy and tolerability of buprenorphine TDS in diabetic patients with chronic pain. Eur J Pain 2006;10 (Suppl 1):S176 (Abstr. 673)
   Google Scholar
• Penza P, Maggi L, Martini A, et al. Analgesic effect of transdermal buprenorphine in patients with uncontrolled painful neuropathy. 17th Meeting of European Neurological Society, 2007
   Google Scholar
• Pota V, Maisto M, Pace M, et al. Association of buprenorphine TDS and pregabalin in the treatment of low back pain. Abstract, Clinical – Pharmacotherapy, Eur J Pain 2007;11:83
   PubMedGoogle Scholar
• Evangelista M, Cappa B. Neuropathic chronic pain following traumatic brachial plexus total section managed by transdermal buprenorphine patch (TDS): original case report. Eur J Pain 2007;11:143
   Google Scholar
• Budd K. High dose buprenorphine for postoperative analgesia. Anaesthesia 1981;36:900-3
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Cancer Care 2007;15:441-4
   PubMed Web of Science ®Google Scholar
• Menten B, van den Eynden, B. Eur J Pain 2006;10(Suppl 1):S144 (Abstr. 546).
   Google Scholar
• Sittl R, Likar R, Nautrup B. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in cancer and non-cancer patients: results of a retrospective cohort study. Clin Ther 2005;27:225-37
   PubMed Web of Science ®Google Scholar
• Freye E. Opioid rotation from high dose morphine to transdermal buprenorphine (Transtec®) in chronic pain patients -- practical implications. Pain Pract 2007;7:123-9
   PubMedGoogle Scholar
• Sittl R, Nuijten M. Nautrup B. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005;27:1022-31
   PubMed Web of Science ®Google Scholar
• Barutell C, Camba A, González-Escalada JR, et al. High dose transdermal buprenorphine for moderate to severe pain in Spanish centres – a retrospective multicentre safety and efficacy study. Pain Pract 2008;8:355-61
   PubMedGoogle Scholar
• Camba MA, Rodríguez-López MJ, Muriel C. Buprenorphine TSD in the treatment of chronic nociceptive, neuropathic and cancer-related pain. J Appl Ther Res 2007;6:3-13
   Google Scholar
• Mercadante S. Casuccio A, Tirelli W, et al. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer 2008 (e-pub ahead of print 23 December)
   Google Scholar
• Pergolizzi J, Bogar RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, oxycodone). Pain Pract 2008;8:287-313
   PubMedGoogle Scholar
• Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage 2008;36:117-25
   PubMed Web of Science ®Google Scholar
• Schmitz S, Bruch H-R, Hagen-Aukamp C. Transdermal buprenorphine in patients with cancer-related pain in oncological practice. J App Ther Res 2008;6:20-31
   Google Scholar
• Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008;3:421-30
   PubMed Web of Science ®Google Scholar
• Zarth, R. Comparison of buprenorphine, morphine sulphate and fentanyl citrate as rescue medication for breakthrough pain in cancer patients. J Appl Ther Res 2008;6:15-19
   Google Scholar